The FDA granted its blessing to Lymphoseek, the first new lymph-node mapping drug in more than 30 years. The Navidea Biopharmaceuticals ($NAVB) product uses a receptor-targeted radioactive tracer to identify nodes that contain cancer cells, in patients who are undergoing surgery.